Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 64INDUSTRY 29NIH 10NETWORK 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Prostatic Diseases 1Lung Neoplasms 1ATM Gene Mutation 1

Interventions

Radiotherapy 299Cisplatin 263Cyclophosphamide 229Doxorubicin 176Paclitaxel 166Vincristine 160Carboplatin 149Filgrastim 139Etoposide 139Gemcitabine 118Fluorouracil 113Docetaxel 112Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 91Leucovorin 90Granulocyte Colony-Stimulating Factor 74Specimen Handling 65Magnetic Resonance Spectroscopy 61Capecitabine 59Irinotecan 58Radiation 54Ifosfamide 51Oxaliplatin 48Daunorubicin 48Temozolomide 47Radiotherapy, Conformal 47Platinum 47Peripheral Blood Stem Cell Transplantation 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Interventional × talazoparib × Clear all
NCT06582628 2024-12-02

TEAM PC

Fundacion Oncosur

Phase 2 Recruiting
78 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms

NCT04173507 2024-09-03

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Completed
47 enrolled 17 charts
Thoracic

Lung Neoplasms

NCT03377556 2021-06-23

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2 Completed
51 enrolled 18 charts

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡